Epizyme prices IPO at $15, the high end of the range
Epizyme, a biotech developing therapeutics for patients with genetically defined cancers, raised $77 million by offering 5.1 million shares at $15, the high end of the range of $13 to $15. Epizyme plans to list on the NASDAQ under the symbol EPZM. Epizyme initially filed confidentially on 3/22/2013. Citi, Cowen & Company and Leerink Swann acted as lead managers on the deal.